You are here

Home » Content

Metabolik sendrom ile panik bozukluk arasındaki ilişki

Psychosomatıc dısorders relatıonshıp between metabolıc syndrome and panıc dısorder

Journal Name:

  • Abant Tıp Dergisi

Publication Year:

  • 2016
DOI: 
10.5505/abantmedj.2016.24482

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
OBJECTİVE: Metabolic syndrome (MS) is characterized by central obesity, hyperglycemia, dyslipidemia and hypertension. In recent years, many studies have investigated the prevalence of MS among psychiatric patients. İn this study, we aimed to investigate the frequency of MS in patients with Panic Disorder (PD). METHODS: Fifty-nine age and sex-matched patients with PD (31 female and 28 male) and healthy subjects (35 female and 24 male) were included in this study. Panic disorder was diagnosed using DSM-IV criteria. MS was diagnosed according to the NCEP ATP (National Cholesterol. Education Program Adult Treatment Panel) (1) Abdominal obesity (2) A high triglyceride (TG) level (3) A low HDL(High-density lipoprotein) cholesterol level (4) A high blood pressure (BP) (5) A high fasting blood glucose (FBG). RESULTS: The mean age of PD patients group was 42.2±12.1 and the mean age of control group was 40.7±12.7 (p=0.491). The frequency of MS in patients with PD was significantly higher than in the healthy control group (46% vs 13%, p<0.001). The differences of MS frequency between PD and healthy group were mainly driven by diastolic blood pressure TG level and waist circumference (WC) (p=0.001 p=0.022 p=0.0016, respectively). In terms of in HDL and FBG there were no differences between the patient and control groups. CONCLUSION: The frequency of MS was increased in patients with PD. This was mainly due to higher frequency of increased diastolic BP, TG level and WC.
Bookmark/Search this post with
Abstract (Original Language): 
AMAÇ: Metabolik sendrom (MS) santral obezite, hiperglisemi, dislipidemi ve hipertansiyon ile karakterizedir. Son yıllarda birçok çalışmada psikiyatri hastaları arasında MS sıklığı araştırılmıştır. Bu çalışmada, Panik bozukluğu (PB) olan hastalarda MS sıklığını araştırmayı amaçladık. YÖNTEM: Panik Bozukluğu olan yaş ve cinsiyet uyumlu hasta 59 hasta (31 kadın ve 28 erkek) ve 59 sağlıklı kontrol grubu (35 kadın ve 24 erkek) çalışmaya alındı. DSM-IV kriterleri kullanılarak PB tanısı kondu. Metabolik sendrom tanısı NCEP ATP III (Ulusal Kolesterol. Eğitim Programı Erişkin Tedavi Paneli) önerileri doğrultusunda (1) Abdominal obezite (2) yüksek trigliserid (TG) düzeyi (3) Düşük HDL (yüksek yoğunluklu lipoprotein) kolesterol düzeyi (4) yüksek kan basıncı (KB) (5) yüksek açlık kan şekeri (AKŞ) seviyesine göre konuldu. BuLgular: Panik Bozukluk hasta grubunun yaş ortalaması 42.2 ± 12.1 ve kontrol grubunun yaş ortalaması 40.7 ± 12.7 (p = 0.491) idi. Panik bozukluğu olan hastalarda MS sıklığı sağlıklı kontrol grubuna göre anlamlı olarak daha yüksek idi (% 46 ve 13% , p <0.001). İki grup arasında yapılan karşılaştırmada metabolik sendrom kriterlerinden diyastolik kan basıncı, TG düzeyi ve bel çevresi (BÇ) anlamlı olarak panik bozukluk hastalarında yüksek bulunmuştur (p = 0.001, p = 0.022, p = 0.0016, sırasıyla). Kolesterol-HDL ve AKŞ açısından hasta ve kontrol grupları arasında fark yoktu. SONUÇ: Panik Bozukluk hastalarında MS sıklığı artmaktadır. Bu artışın temel sebebi, artmış diyastolik kan basıncı, TG düzeyi ve bel çevresidir.
FULL TEXT (PDF): 
PDF icon arastirmax-metabolik-sendrom-ile-panik-bozukluk-arasindaki-iliski.pdf
  • 2
91
100
  • Turkish

REFERENCES

References: 

1. Bloomgarden ZT. American Association of Clinical Endocrinologists (AACE) consensus conference on the insulin resistance syndrome: 25-26 August 2002, Washington, DC. Diabetes Care 2003;26:1297-303.
2. Hori Y, Nakatani K, Morioka K, Katsuki A, Gabazza EC, Yano Y, Nobori T, Adachi Y, Sumida Y. Insulin enhanced thrombin-activable fibrinolysis inhibitor expression through PI3 kinase/Akt pathway. Int J Mol Med 2005;15:265-8.
3. Calles-Escandon J, Mirza SA, Sobel BE, Schneider DJ. Induction of hyperinsulinemia combined with hyperglycemia and hypertriglyceridemia increases plasminogen activator inhibitor 1 in blood in normal human subjects. Diabetes 1998;47:290-3.
4. Lakka HM, Laaksonen DE, Lakka TA. The metabolic syndrome and total cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:27092716
5. Singh RB, Gupta S, Dherange P, De Meester F, Wilczynska A, Alam SE, Pella D, Wilson DW: Metabolic syndrome: a brain disease. Can J Physiol Pharmacol 2012, 90:1171–1183.
6. Chang HH, Chou CH, Chen PS, Gean PW, Huang HC, Lin CY, Yang YK, Lu RB:
Kaya Y ve ark.
Abant Med J 2016;5(2):91 - 100 98
High prevalence of metabolic disturbances in patients with bipolar disorder in Taiwan. J Affect Disord 2009, 117:124–129
7. Kim B, Kim SJ, Son JI, Joo YH: Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients. J Affect Disord 2008, 105:45–52.
8. McElroy SL, Keck PE: Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry 2014, 75:46–61
9. Van Winkel R, van Os J, Celic I: Psychiatric diagnosis as an independent risk factor for metabolic disturbances: results from a comprehensive, naturalistic screening program. J Clin Psychiatry 2008, 69:1319–1327.
10. Taylor V, MacQueen G: Associations between bipolar disorder and metabolic syndrome: a review. J Clin Psychiatry 2006, 67:1034–1041
11. McIntyre RS, Rasgon NL, Kemp DE, Nguyen HT, Law CW, Taylor VH,
Woldeyohannes HO, Alsuwaidan MT, Soczynska JK, Kim B, Lourenco MT, Kahn LS, Goldstein BI: Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep 2009, 9:51–59.
12. Goldbacher EM, Bromberger J, Matthews KA: Lifetime history of major depression predicts the development of the metabolic syndrome in middle-aged women. Psychosom Med 2009, 71:266–272.
13. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on the Detection, Diagnosis, and Treatment of High Cholesterol in Adults: (Adult Treatment Panel III). JAMA 2001; 285: 2486-97
14. Moreno PR, Fuster V. New aspects in the pathogenesis of diabetic atherothrombosis. J Am Coll Cardiol 2004;44:2293-300.
15. Aytekin Oğuz,Mehmet Uzunlulu,Aysun Sevük, Yaşlıda Metabolik Sendrom ve Önemi,Akademik Geriatri,2011;3(2).
16. Casey DE. Metabolic issues and cardiovascular disease in patients with psychiatric disorders. Am Jour Med 2005; 118:15-22
17. Mehmet Ali Nahit Şendur, Gülay Sain Güven , Metabolik Sendroma Güncel Bakış, İç Hastalıkları Dergisi 2011; 18: 125-131.
18. Chengappa KN, Levine J, Gershon S. Lifetime prevalence of substance or alcohol abuse and dependence among
Kaya Y ve ark.
Abant Med J 2016;5(2):91 - 100 99
subjects with bipolar I and II disorders in a voluntary registry. Bipolar Disord 2000; 2(3);191-195
19. Fagiolini A, Frank E, Scott JA, Türkin S, Kupfer DJ. Metabolie syndrome in bipolar disorder:findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disorder 2005; 7:424-430
20. Heiskanen T, Niskanen L, Lyytikainen L. Metabolic Syndrome In Patients With Schizophrenia. J Clin Psychiatry 2003; 64:575-579
21. Landsberg L. Role of the sympathetic adrenal system in the pathogenesis of the insulin resistance syndrome. Acad Scien 1999; 892: 84-90
22. Traisi RJ, Weiss ST, Parker DR. Relation of obesity and diet to sympathetic nervous system activity. J. Hypertens 1991; 17:669-677 125.
23. Rosmond R. Bjorntorp P. Blood pressure in relation to obesity, insulin and the hypothalamic-pituitary-adrenal axis in Swedish men. J. Hypertens 1998; 16:1721-1726 126.
24. Chrousos G, Gold PW. The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis. JAMA 1992; 267:1244-1252
25. Cassidy F, Ritchie JC, Carroll BJ. Plasma dexamethasone concentration and
Cortisol response during manic episodes. Biol Psychiatry 1998; 43: 747-754
26. DeFronzo RA, Ferrannini E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14:173-194
27. Bjorntorp P. The regulation of adipose tissue distribution in humans. Int J Obes Relat Metab Disord 1996; 20:291-302
28. Yehuda R. Stress and glucocorticoid [letter]. Science 1997; 275:1662-1663
29. Bschor T, Adli M, Baethge C. Lithium augmentation increases the ACTH and Cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology 2002; 27:470-478
30. Hammen CL. Stress and the course of unipolar and bipolar disorders. In Mazure CM, ed. Progress in Psychiatry, Does Stress Cause Psychiatric Illness Washington, DC Am Psych Press 1995; 46:87-110 129.
31. Post RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry 1992; 149:999-1010 130.
32. McEwen BS. Protection and damage from acute and chronic stress:
Kaya Y ve ark.
Abant Med J 2016;5(2):91- 100 1 00
allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Acad Scien 2004; 1032:1-7 131.
33. Rubin RT. Pharmacoendocrinology of major depression. Eur Arch Psych Neurol 1989; 238:259-267
34. Rosmond R, Bjorntorp P. The interactions between hypothalamic-pituitaryadrenal axis activity, testosterone,
insulin-like growth factor I and abdominal obesity with metabolism and blood pressure in men. Int J Obes Relat Metab Disord 1998; 22:1184-1196

Thank you for copying data from http://www.arastirmax.com